CMS officials on monday in a preliminary decision rejected a request from Cyberonics for Medicare coverage of the vagus nerve stimulator as a treatment for depression.
Medicare currently covers VNS, the only implantable device that FDA has approved as a treatment for depression, as a treatment for epilepsy in certain patients. According to CMS, “there is sufficient evidence to conclude that vagus nerve stimulation is not reasonable and necessary for treatment of resistant depression.”